linjc16/ctgov huggingface dataset:
Oxidized Regenerated Cellulose to Decrease Vaginal Cuff Complications

Study Overview
=================
Brief Summary
-----------------
The goal of the investigators study is to determine whether the use of oxidized regenerated cellulose reduces the risk of vaginal cuff cellulitis, pelvic abscess, or vaginal cuff dehiscence in patients undergoing laparoscopic hysterectomy. The investigators hypothesize that the use of oxidized regenerated cellulose will reduce the risk of vaginal cuff cellulitis, pelvic abscess, and vaginal cuff dehiscence in patients undergoing laparoscopic hysterectomy.

Detailed Description
-----------------
Structured non-woven absorbable hemostat (or oxidized regenerated cellulose) was designed and marketed for its hemostatic properties. It is used in our practice to achieve hemostasis at the site of the vaginal cuff closure during laparoscopic hysterectomy. While the hemostatic properties of oxidized regenerated cellulose are well known and documented, there is newer research to suggest that oxidized regenerated cellulose may have antimicrobial activity. One In vitro study investigated the antimicrobial activity of oxidized regenerated cellulose products against multiple antibiotic resistant microorganisms and found that the antimicrobial affect of the oxidized regenerated cellulose products was significantly greater than that of the controls. There are a limited number of studies investigating the antimicrobial activity of oxidized regenerated cellulose products in vivo (and none in gynecologic surgery).

Official Title
-----------------
Use of Structured Non-woven Absorbable Hemostat (or Oxidized Regenerated Cellulose) to Decrease Vaginal Cuff Dehiscence Rate in Laparoscopic Hysterectomy

Conditions
-----------------
Vaginal Cuff Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female, ages 20-80, undergoing laparoscopic hysterectomy Exclusion Criteria: malignant indications for hysterectomy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Oxidized regenerated cellulose<br>Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of vaginal cuff complications | Incidence of vaginal cuff complicationsincluding vaginal cuff dehiscence, vaginal cuff cellulitis, and vaginal cuff abscess | postoperative |
Correlating Ic/Pbs Symptoms With Urine Biomarkers

Study Overview
=================
Brief Summary
-----------------
Completion of a brief survey tool and providing an urine specimen. The study purpose is to improve our understanding of interstitial cystitis and painful pelvic syndrome.

Detailed Description
-----------------
The purpose of the study is to improve our understanding of the IC/PBS and develop new treatments. Participation in the study will allow us to compare clinical information, obtained by completion of a brief survey, with substances found in the a urine specimen that is donated to the Beaumont Biobank.

Official Title
-----------------
Correlating Ic/Pbs Symptoms With Urine Biomarkers

Conditions
-----------------
Interstitial Cystitis, Pelvic Pain

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Men and women with interstitial cystitis/painful bladder syndrome greater than 18 years old Male and female controls without a history of IC/PBS diagnosis Exclusion: 1. Unable to complete questionnaires and/or give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients will be asked to provide a urine specimen and complete a questionnaire. | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To correlate IC/PBS symptoms with urine biomarkers |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Interstitial cystitis, pelvic pain
Reconstruction of the Anterolateral Ligament (ALL) With Revision Anterior Cruciate Ligament (ACL) Surgery

Study Overview
=================
Brief Summary
-----------------
Patients with combined Anterolateral ligament (ALL) reconstruction- Anterior cruciate ligament (ACL) revision will have a better rotational knee stability and therefore better patient reported outcome measure (PROM) scores compared to patients, who have ACL revision surgery without ALL reconstruction.

Official Title
-----------------
Effect of Reconstruction of the Anterolateral Ligament (ALL) in Combination With Revision Anterior Cruciate Ligament (ACL) Surgery. A Clinical Randomized Trial

Conditions
-----------------
Rupture of Anterior Cruciate Ligament, Anterolateral Ligament Reconstruction

Intervention / Treatment
-----------------
* Procedure: ALL reconstruction (Anterolateral ligament)
* Procedure: ACL revision (Anterior cruciate ligament )


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ACL revision surgery indication Exclusion Criteria: Patients with difficulties of understanding danish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Isolated ACL-revision<br>The standard operation with an isolated Anterior cruciate ligament. | Procedure: ACL revision (Anterior cruciate ligament )<br> <br> |
| Other: Combined ACL and ALL surgery<br>An operation with an Anterior cruciate ligament combined with an anterolateral ligament. | Procedure: ALL reconstruction (Anterolateral ligament)<br> <br> Procedure: ACL revision (Anterior cruciate ligament )<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in The Knee Numeric-Entity Evaluation Score (KNEES) | questionaire | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in Knee injury and Osteoarthritis Outcome Score (KOOS) | questionaire | 12 Months | 
| Difference in KT-1000 | Objective Knee stability | 12 Months | 
| Difference in TEGNER functional score | questionaire | 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laxity, Knee, Rupture, ALL
Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to explore the importance of migraine genes on the headache/migraine responses after GTN in FHM-patients and healthy volunteers.

Detailed Description
-----------------
Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers. After systemic administration GTN is transformed to nitric oxide (NO). Treatment of spontaneous migraine attacks with an inhibitor of NO is effective in 60% of patients. These data show that NO is involved in both initiation and maintenance of migraine attack. The importance of migraine genes is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Official Title
-----------------
Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine

Conditions
-----------------
Familial Hemiplegic Migraine

Intervention / Treatment
-----------------
* Drug: Nitroglycerine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of familial hemiplegic migraine (IHS-classification criteria) Exclusion Criteria: Patients and controls: A history of cerebrovascular disease and other CNS- disease A history of serious somatic and mental disease A history suggesting ischaemic heart disease A history of hypo- or hypertension Daily intake of medication apart from oral contraceptives Abuse of alcohol or medicine (opioid analgesics). Pregnant or breastfeeding women. On the study day: No intake of a simple analgesic in the previous 48 hours No headache in the previous 48 hours
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients<br>GTN-infusion | Drug: Nitroglycerine<br>* Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min<br>|
| Active Comparator: Controls<br>GTN-infusion | Drug: Nitroglycerine<br>* Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Migraine and associated symptoms |  | 0-14 h | 
| Migraine aura |  | 0 - 14 h | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Familial Hemiplegic Migraine
MultiPoint Pacing Mapping Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize left ventricular acute hemodynamic and electrical responses during cardiac resynchronization therapy (CRT) with different Multipoint Pacing (MPP) settings, and assess the relationship between electrical activation patterns and hemodynamic measurements during these pacing settings.

Official Title
-----------------
MultiPoint Pacing Mapping Study

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be scheduled to undergo or have received within the past 30 days an implant of a SJM (St. Jude Medical) MPP CRT-D system with approved standard indication by ESC (European Society of Cardiology) / EHRA (European Heart Rhythm Association) Guidelines Have the ability to provide informed consent for study participation and be willing and able to comply with the Clinical Investigation Plan (CIP) described evaluations and follow-up schedule Be in sinus rhythm Exclusion Criteria: Complete AV (atrioventricular) block Permanent atrial fibrillation Have a recent myocardial infarction within 40 days prior to enrollment Have undergone cardiac surgery or coronary revascularization procedure within 3 months prior to enrollment or be scheduled for such procedures in the following 7 months Have had a recent CVA (cerebrovascular accident) or TIA (transient ischemic attack) within 3 months prior to enrollment Have had intravenous inotropic support in the last 30 days Be less than 18 years of age Be pregnant or plan to become pregnant over the next 7 months Have significant peripheral vascular disease Have LV thrombus Significant aortic valve disease or replacement Mitral valvular disease Contraindicated for Gadolinium contrast agent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left ventricular (LV) dP/dt Max (maximum change in pressure over time) in mmHg/s during different pacing settings |  | up to 30 days post-implant |
Optical Genome Mapping in Hematological Malignancies

Study Overview
=================
Brief Summary
-----------------
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer

Official Title
-----------------
Optical Genome Mapping in Hematological Malignancies

Conditions
-----------------
MDS, ALL, Other Hematologic Malignant Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minor/Major Patients Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. No objection made or consent given Exclusion Criteria: Patients under judicial protection (guardianship, curatorship, ...), Refusal to participate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer | identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH. | 2021-2026 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification of new chromosomal abnormalities of clinical relevance. |  | 2021-2026 | 
| identification of new chromosomal anomalies involved in oncogenic pathways |  | 2021-2026 |
Unmet Health Needs Among Students

Study Overview
=================
Brief Summary
-----------------
The concept of unmet health needs refers to the difference between health services thought necessary to treat a particular health problem and services actually received. A person who perceived the need to receive medical services but who has not obtained these services has unmet health care needs. Unmet health care may result from limited availability or unavailability of health care services, when or where they were required. Also it can be caused from individual accessibility problem, such as cost or transportation, or from acceptability problem, such as attitude toward and knowledge about health care.so, the investigators will assess the unmet health needs and identify the causes.

Official Title
-----------------
Unmet Health Needs Among Sohag University Students

Conditions
-----------------
Unmet Health Needs

Intervention / Treatment
-----------------
* Other: Unmet health needs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all students who are more than 18 years old and approve to participate in the study Exclusion Criteria: any students who refuse to participate in the study or who are under 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the unmet health needs of Sohag university students. | Identify the most important causes of unmet health needs among students by answering the questionnaire | Assess the unmet health needs of the students during the last 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the students' awareness and attitude towards Sohag University Medical Center | The students will answer the questionnaire to know if they know about the University Medical Center or not and how the evaluate it. | Assess the students' use of the University Medical Center during the last year |
Efficacy and Safety of Pactimibe in Patients With Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
The effect of pactimibe on the reduction of atherosclerosis in the carotid artery will be assessed using carotid ultrasound

Official Title
-----------------
Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound

Conditions
-----------------
Atherosclerosis

Intervention / Treatment
-----------------
* Drug: Pactimibe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Increased cardiovascular risk (i.e. history of myocardial infarction, stroke, diabetes mellitus, left ventricular hypertrophy) Intima-media thickness greater than or equal to 0.8 mm as measured by ultrasonography Negative pregnancy test for females Exclusion Criteria: Whole blood donation (greater than or equal to 450 ml) during the last three months before study start Unstable angina, congestive heart failure or uncontrolled hypertension Renal disease including nephrectomy and/or renal transplant Hepatic disease or abnormal liver function parameters Drug abuse or alcohol addiction

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pactimibe|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of pactimibe versus placebo on the progression of atherosclerosis |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of pactimibe versus placebo in patients with atherosclerosis |  |  |
Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Fibroblast Growth Factor 23 (FGF23) is a molecule that has been implicated in the homeostasis of phosphorus. Elevated FGF23 levels are well-documented in patients with Chronic Kidney Disease (CKD) and are inversely correlated with Glomerular Filtration Rate (GFR). FGF23 levels are also predictive of progression of CKD and predict mortality in CKD. Although studies in normal individuals suggest that phosphorus intake is related to FGF23 levels, the effect of dietary and pharmacologic phosphate restriction on FGF23 levels in patients with CKD has never been reported. Our objectives are to determine if phosphate reduction through the use of non-calcium based phosphate binder will decrease serum FGF23 levels. The investigators will also be investigating associations of elevation in FGF 23 levels with commonly encountered co-morbidities in CKD patients such as Coronary Artery Disease, Diabetes Mellitus, and Hypertension.

Official Title
-----------------
Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

Conditions
-----------------
Chronic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Sevelamer Carbonate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults between ages 18-80 years old, with a GFR less than or equal to 50 ml/min/1.73 m2 as determined by the Modification of Diet in Renal Disease (MDRD) formula will be included. Exclusion Criteria: Patients will be excluded if they have a history of renal transplant or are pregnant. In addition, patients with dysphagia, swallowing disorders, severe GI motility disorders, severe constipation, history of major gastrointestinal surgery and patients taking levothyroxine for hypothyroidism will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Patients enrolled will receive Renvela for a 3 month time frame. | Drug: Sevelamer Carbonate<br>* Sevelamer 800 mg by mouth three times daily with meals for 3 months<br>* Other names: Renvela;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease | Determine if phosphate reduction through the use of non-calcium based phosphate binders will decrease serum FGF23 levels | March 2011-June 2012 |